Abolis Overview
- Status
-
Private
- Employees
-
66
- Latest Deal Type
-
2ndary - Private
- Investors
-
8
Abolis General Information
Description
Developer of microbial systems and industrial biotechnology platforms designed to support ingredient development, process optimisation and product innovation across food, cosmetics, healthcare and chemical industries. The company offers expertise in strain engineering, microbial metabolism, fermentation, bioprocess development, proprietary technologies, and an integrated industrial approach, enabling innovators, manufacturers, and R&D (Research and Development) teams across food, cosmetics, healthcare, and chemical industries improved understanding of complex microbial systems and the development of ingredients, biotics, and scalable industrial applications.
Contact Information
Website
www.abolis.frCorporate Office
- 5 rue Henri Auguste Desbruères
- Genopole Campus 1, Bâtiment 6, EVRY-COURCOURONNES
- 91000 Paris
- France
Corporate Office
- 5 rue Henri Auguste Desbruères
- Genopole Campus 1, Bâtiment 6, EVRY-COURCOURONNES
- 91000 Paris
- France
Abolis Timeline
Abolis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Secondary Transaction - Private | 01-Apr-2026 | Completed | Generating Revenue/Not Profitable | |||
| 7. Later Stage VC (Series A) | 31-Jul-2024 | Completed | Generating Revenue/Not Profitable | |||
| 6. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 5. Accelerator/Incubator | Completed | Startup | ||||
| 4. Seed Round | 23-Feb-2017 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | Completed | Startup | ||||
| 2. Accelerator/Incubator | 27-Jun-2014 | $122K | $122K | Completed | Startup | |
| 1. Grant | 21-Mar-2014 | $276K | Completed | Startup |
Abolis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A Shares | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Abolis Comparisons
Industry
Financing
Details
Abolis Competitors (2)
One of Abolis’s 2 competitors is Bota Biosciences, a Venture Capital-Backed company based in Hangzhou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bota Biosciences | Venture Capital-Backed | Hangzhou, China | ||||
| Acies Bio | Venture Capital-Backed | Ljubljana, Slovenia |
Abolis Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Abolis Patents
Abolis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026022315-A1 | Combinations of synthetic yeast promoters | Pending | 24-Jul-2024 | ||
| WO-2026022317-A1 | Synthetic yeast promoters | Pending | 24-Jul-2024 | ||
| EP-4437087-A1 | Method for the biosynthesis of caffeic acid and ferulic acid | Pending | 23-Nov-2021 | ||
| US-20250019727-A1 | Method for the biosynthesis of caffeic acid and ferulic acid | Pending | 23-Nov-2021 | ||
| WO-2023094774-A1 | Method for the biosynthesis of caffeic acid and ferulic acid | Inactive | 23-Nov-2021 | C12P7/42 |
Abolis Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Abolis Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BOLD (Business Opportunities for L'Oréal Development) | Corporate Venture Capital | Minority | ||
| Clay Capital (Singapore) | Venture Capital | Minority | ||
| DeepTech & Climate Fonds | Venture Capital | Minority | ||
| Evonik Venture Capital | Corporate Venture Capital | Minority | ||
| Icos Capital | Venture Capital | Minority |
Abolis Investments (1)
Abolis’s most recent deal was a Spin-Off with Microbiome Studio.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Microbiome Studio | Spin-Off | Biotechnology |
Abolis FAQs
-
Where is Abolis headquartered?
Abolis is headquartered in Paris, France.
-
What is the size of Abolis?
Abolis has 66 total employees.
-
What industry is Abolis in?
Abolis’s primary industry is Biotechnology.
-
Is Abolis a private or public company?
Abolis is a Private company.
-
What is Abolis’s current revenue?
The current revenue for Abolis is .
-
How much funding has Abolis raised over time?
Abolis has raised $44.8M.
-
Who are Abolis’s investors?
BOLD (Business Opportunities for L'Oréal Development), Clay Capital (Singapore), DeepTech & Climate Fonds, Evonik Venture Capital, and Icos Capital are 5 of 8 investors who have invested in Abolis.
-
Who are Abolis’s competitors?
Bota Biosciences and Acies Bio are competitors of Abolis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
